US 11,692,030 B2
Biomarkers and methods for detection of seizures and epilepsy
Todd Wallach, Overland Park, KS (US); Elisa A. Waxman, Overland Park, KS (US); John Gledhill, Overland Park, KS (US); Richard St. Clair, Overland Park, KS (US); and Elizabeth Brand, Overland Park, KS (US)
Assigned to Cognizance Biomarkers, LLC, Miami, FL (US)
Filed by EVOGEN, INC., Overland Park, KS (US)
Filed on Nov. 15, 2019, as Appl. No. 16/685,149.
Application 16/685,149 is a continuation of application No. PCT/US2018/032956, filed on May 16, 2018.
Claims priority of provisional application 62/506,878, filed on May 16, 2017.
Prior Publication US 2020/0299377 A1, Sep. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); G16H 10/40 (2018.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/70 (2018.01); G16H 50/20 (2018.01); G01N 33/68 (2006.01)
CPC C07K 16/244 (2013.01) [G01N 33/6896 (2013.01); G16H 10/40 (2018.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01); G01N 2333/521 (2013.01); G01N 2333/525 (2013.01); G01N 2333/5446 (2013.01); G01N 2800/2857 (2013.01); G01N 2800/52 (2013.01)] 3 Claims
 
1. A method of treating epilepsy in a patient in need of epilepsy treatment, the method comprising:
contacting a blood sample obtained from the patient with one or more antibodies targeting interleukin-16 (IL-16), wherein the one or more antibodies are capture, detect or a combination thereof antibodies;
measuring the concentration of IL-16 in the blood sample;
comparing the concentration of IL-16 in the blood sample to the concentration of IL-16 in a control;
determining that the concentration of IL-16 in the blood sample obtained from the patient is elevated relative to the control, thus determining that the patient is in need of epilepsy treatment; and
treating the patient for epilepsy, wherein the treating comprises administering to the patient one or more therapeutic agents selected from the group consisting of phenytoin, fosphenytoin, midazolam, pregabalin, acetazolamide, methsuximide, ethotoin, piracetam, nitrazepam, paraldehyde, stiripentol, vigabatrin, brivaracetam, perampanel, rufinamide, lurasidone HCl, carbamazepine, clobazam, clonazepam, diazepam, divalproex, eslicarbazepine acetate, ethosuxemide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, primidone, tiagabine, topiramate, valproic acid, zonisamide, cannabis-based drugs, and pharmaceutically acceptable salts, prodrugs, and derivatives thereof.